Scientists from VIDO-InterVac and Temple University in Philadelphia, Penn., have demonstrated that a salmonella biofilm protein can cause autoimmune responses and arthritis in animals.
A COVID-19 vaccine candidate developed by VIDO-InterVac has cleared another major milestone in moving towards human clinical trials: the novel vaccine has proven highly effective in ferrets, one of the commonly used animal models for COVID-19.
VIDO-InterVac and NRC announced a collaboration to accelerate the development and production of a candidate COVID-19 antigen in mammalian cells.
